journal article·2024-10Open access

Delivery of extracellular vesicles loaded with immune checkpoint inhibitors for immunotherapeutic management of glioma

Shang-Wen Lin, Cheng-Ping Yu, Jui-Chen Tsai, Yan-Jye Shyong

Abstract

Glioma is a common primary malignant brain tumor with low survival rate. Immunotherapy with immune checkpoints inhibitors (ICI) can be a choice for glioma management, and extracellular vesicles (EVs) are recognized as a potential drug delivery system for various disease management due to their enhanced barrier permeation ability and immunomodulatory effect. The aim of this study is to develop ICI-loaded EVs (ICI/EV) that have sufficient efficacy in managing glioma. Calcium phosphate particles (CaP) were used to stimulate the secretion of EVs from murine macrophage cells. CaP conditioning of cells showed an enhanced amount of EVs secretion and macrophage polarization toward a proinflammatory phenotype. The CaP-induced EVs were shown to polarize macrophages into proinflammatory phenotype in vitro, as correlated with the conditioning method. ICI/EVs were successfully prepared with high loading efficiency using the sonication method. The EVs can be distributed throughout the entire brain upon intranasal administration and facilitate ICIs distribution into glioma lesion. Combinatory treatment with ICI/EVs showed benefit in glioma-bearing mice by reducing their tumor volume and prolonging their survival. Cytotoxic T cell infiltration, polarization of tumor-associated macrophage, and lower tumor proliferation were observed in ICI/EVs-treated mice. The developed ICI/EVs showed promise in immunotherapeutic management of glioma.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Extracellular vesicles in disease · MicroRNA in disease regulation · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (66)

Show source-provided references
1. World health organization classification of central nervous system tumors, continuum (Minneap Minn) 23(6
2. Current challenges and opportunities in treating glioblastoma10.1124/pr.117.014944 ↗
3. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment
4. Is immunotherapy the future of glioblastoma treatment?
5. Long acting tariquidar loaded stearic acid-modified hydroxyapatite enhances brain penetration and antitumor effect of temozolomide10.1016/j.ejpb.2024.114231 ↗
6. Bioinspired adaptive microdrugs enhance the chemotherapy of malignant glioma: beyond their nanodrugs10.1002/adma.202405165 ↗
7. Immunotherapy in gliomas: are we reckoning without the innate immunity?10.1177/2058738419843378 ↗
8. Next generation of immune checkpoint inhibitors and beyond10.1186/s13045-021-01056-8 ↗
9. Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy10.1038/s41467-019-11719-3 ↗
10. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model10.1158/2326-6066.CIR-15-0151 ↗
11. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial10.1093/neuonc/noac099 ↗
12. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter10.1093/neuonc/noac116 ↗
13. Circulating immune cell and outcome analysis from the phase II study of PD-L1 blockade with durvalumab for newly diagnosed and recurrent glioblastoma10.1158/1078-0432.CCR-21-4064 ↗
14. Extracellular vesicles: opportunities and challenges for the treatment of renal diseases
15. Drug delivery with extracellular vesicles: from imagination to innovation10.1021/acs.accounts.9b00109 ↗
16. Using exosomes, naturally-equipped nanocarriers, for drug delivery10.1016/j.jconrel.2015.07.030 ↗
17. Fruit-derived extracellular-vesicle-engineered structural droplet drugs for enhanced glioblastoma chemotherapy10.1002/adma.202304187 ↗
18. Macrophage-derived extracellular vesicles: diverse mediators of pathology and therapeutics in multiple diseases10.1038/s41419-020-03127-z ↗
19. Exosome-guided phenotypic switch of M1 to M2 macrophages for cutaneous wound healing10.1002/advs.201900513 ↗
20. Exploration and functionalization of M1-macrophage extracellular vesicles for effective accumulation in glioblastoma and strong synergistic therapeutic effects10.1038/s41392-022-00894-3 ↗
21. M1 macrophage-derived exosomes and their key molecule lncRNA HOTTIP suppress head and neck squamous cell carcinoma progression by upregulating the TLR5/NF-κB pathway10.1038/s41419-022-04640-z ↗
22. Exosomes from M1-polarized macrophages potentiate the cancer vaccine by creating a pro-inflammatory microenvironment in the lymph node10.1016/j.ymthe.2017.02.007 ↗
23. Exosome release is regulated by a calcium-dependent mechanism in K562 cells10.1074/jbc.M301642200 ↗
24. Ca2+ mediates extracellular vesicle biogenesis through alternate pathways in malignancy10.1080/20013078.2020.1734326 ↗
25. A Ca2+-stimulated exosome release pathway in cancer cells is regulated by Munc13-410.1083/jcb.201710132 ↗
26. Gene delivery by hydroxyapatite and calcium phosphate nanoparticles: a review of novel and recent applications
27. Design of calcium phosphate ceramics for drug delivery applications in bone diseases: a review of the parameters affecting the loading and release of the therapeutic substance10.1016/j.jconrel.2017.02.012 ↗
28. Calcium phosphate particles stimulate interleukin-1β release from human vascular smooth muscle cells: a role for spleen tyrosine kinase and exosome release10.1016/j.yjmcc.2017.12.007 ↗
29. Nano-hydroxyapatite accelerates vascular calcification via lysosome impairment and autophagy dysfunction in smooth muscle cells
30. Calcium phosphate particles stimulate exosome secretion from phagocytes for the enhancement of drug delivery10.1016/j.colsurfb.2018.07.037 ↗
31. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes10.1038/nbt.1807 ↗
32. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation10.1038/s41551-019-0485-1 ↗
33. Exosomes as drug delivery vehicles for Parkinson's disease therapy10.1016/j.jconrel.2015.03.033 ↗
34. M1 macrophage-derived nanovesicles potentiate the anticancer efficacy of immune checkpoint inhibitors10.1021/acsnano.8b02446 ↗
35. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines10.1080/20013078.2018.1535750 ↗
36. Quantification of pharmacokinetic profiles of PD-1/PD-L1 antibodies by validated ELISAs10.3390/pharmaceutics12060595 ↗
37. Hierarchically nanostructured hydroxyapatite: hydrothermal synthesis, morphology control, growth mechanism, and biological activity10.2147/IJN.S29884 ↗
38. Synthesis and characterization of HA/β-TCP bioceramic powder10.1002/vjch.201800004 ↗
39. Calcium phosphate nanoparticles primarily induce cell necrosis through lysosomal rupture: the origination of material cytotoxicity10.1039/c4tb00056k ↗
40. Cytokines in clinical cancer immunotherapy10.1038/s41416-018-0328-y ↗
41. Basic calcium phosphate crystals induce monocyte/macrophage IL-1β secretion through the NLRP3 inflammasome in vitro10.4049/jimmunol.1001284 ↗
42. Phagocytosis: our current understanding of a universal biological process10.3389/fimmu.2020.01066 ↗
43. Role of particle size in phagocytosis of polymeric microspheres10.1007/s11095-008-9562-y ↗
44. A comprehensive review of calcium electroporation -A novel cancer treatment modality10.3390/cancers12020290 ↗
45. Progesterone analogue protects stressed photoreceptors via bFGF-mediated calcium influx10.1111/ejn.13445 ↗
46. Starvation induces an increase in intracellular calcium and potentiates the progesterone-induced mouse sperm acrosome reaction10.1096/fj.202100122R ↗
47. Starvation and antimetabolic therapy promote cytokine release and recruitment of immune cells10.1073/pnas.1913707117 ↗
48. Macrophage cytokines: involvement in immunity and infectious diseases10.3389/fimmu.2014.00491 ↗
49. Exosomes isolated from two different cell lines using three different isolation techniques show variation in physical and molecular characteristics10.1016/j.bbamem.2020.183490 ↗
50. Topical application of sebacoyl dinalbuphine ester-loaded nanostructured lipid carriers alleviate pruritus in scratching mouse model10.1016/j.ijpharm.2021.120400 ↗
51. Drug delivery of extracellular vesicles: preparation, delivery strategies and applications10.1016/j.ijpharm.2023.123185 ↗
52. In vitro and ex vivo experimental models for evaluation of intranasal systemic drug delivery as well as direct nose-to-brain drug delivery10.1002/bdd.2348 ↗
53. A simple technique to establish a long-term adenovirus mediated gene transfer to the heart of newborn mice10.2174/187152909788488645 ↗
54. Delivery of immunoglobulin G antibodies to the rat nervous system following intranasal administration: distribution, dose-response, and mechanisms of delivery10.1016/j.jconrel.2018.08.006 ↗
55. The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors
56. Changes of IL-6 and IFN-γ before and after the adverse events related to immune checkpoint inhibitors: a retrospective study10.1097/MD.0000000000031761 ↗
57. T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution10.1186/s13046-024-02960-w ↗
58. The microenvironmental landscape of brain tumors10.1016/j.ccell.2017.02.009 ↗
59. Resistance to immune checkpoint blockade: mechanisms, counter-acting approaches, and future directions10.1016/j.semcancer.2022.02.019 ↗
60. Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade10.1016/j.ccell.2017.07.006 ↗
61. Immunotherapy for glioblastoma: the promise of combination strategies10.1186/s13046-022-02251-2 ↗
62. M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages10.1016/j.biomaterials.2021.121137 ↗
63. The 2021 WHO classification of tumors of the central nervous system: a summary10.1093/neuonc/noab106 ↗
64. Distinct tumor microenvironment at tumor edge as a result of astrocyte activation is associated with therapeutic resistance for brain tumor
65. Tumor-secreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model10.1038/labinvest.2011.128 ↗
66. Lin · 2023 · 92